Andere talen Beam Therapeutics Inc.

Aandelen

BEAM

US07373V1052

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
23,13 ^USD	+1,80%		+8,19%	-15,03%

04/04	Insider bij Beam Therapeutics verkocht aandelen ter waarde van $581.617, volgens een recent SEC-document	MT
04/04	Insider bij Beam Therapeutics verkocht aandelen ter waarde van $734.805, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04/04
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04/04
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	27/02
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27/02
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27/02
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27/02
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	30/01
North American Morning Briefing : Microsoft Kicks -2-	30/01
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	29/01
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17/01
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bitcoin ETF's zijn geweldig, maar geen echte crypto: Beam CEO

30 januari 2024 om 20:21 uur